Compare Elder Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA IPCA LABS ELDER PHARMA/
IPCA LABS
 
P/E (TTM) x -0.2 23.7 - View Chart
P/BV x 0.1 8.5 1.2% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 ELDER PHARMA   IPCA LABS
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
IPCA LABS
Mar-19
ELDER PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3801,042 36.5%   
Low Rs188590 31.9%   
Sales per share (Unadj.) Rs491.2298.6 164.5%  
Earnings per share (Unadj.) Rs-3.235.0 -9.1%  
Cash flow per share (Unadj.) Rs14.449.4 29.1%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs376.5247.1 152.4%  
Shares outstanding (eoy) m20.54126.35 16.3%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x0.62.7 21.2%   
Avg P/E ratio x-89.323.3 -382.8%  
P/CF ratio (eoy) x19.716.5 119.4%  
Price / Book Value ratio x0.83.3 22.8%  
Dividend payout %08.6 0.0%   
Avg Mkt Cap Rs m5,833103,108 5.7%   
No. of employees `000NA13.4 0.0%   
Total wages/salary Rs m2,1797,874 27.7%   
Avg. sales/employee Rs ThNM2,807.0-  
Avg. wages/employee Rs ThNM585.8-  
Avg. net profit/employee Rs ThNM329.0-  
INCOME DATA
Net Sales Rs m10,08937,732 26.7%  
Other income Rs m257577 44.5%   
Total revenues Rs m10,34638,309 27.0%   
Gross profit Rs m-7926,901 -11.5%  
Depreciation Rs m3611,824 19.8%   
Interest Rs m2,756189 1,460.7%   
Profit before tax Rs m-3,6535,465 -66.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1251,042 12.0%   
Profit after tax Rs m-654,422 -1.5%  
Gross profit margin %-7.818.3 -42.9%  
Effective tax rate %-3.419.1 -18.0%   
Net profit margin %-0.611.7 -5.5%  
BALANCE SHEET DATA
Current assets Rs m9,24023,778 38.9%   
Current liabilities Rs m9,99810,975 91.1%   
Net working cap to sales %-7.533.9 -22.1%  
Current ratio x0.92.2 42.7%  
Inventory Days Days46104 44.6%  
Debtors Days Days6066 90.9%  
Net fixed assets Rs m10,12420,368 49.7%   
Share capital Rs m206253 81.4%   
"Free" reserves Rs m5,58230,971 18.0%   
Net worth Rs m7,73431,224 24.8%   
Long term debt Rs m4,8891,409 347.1%   
Total assets Rs m22,88245,507 50.3%  
Interest coverage x-0.330.0 -1.1%   
Debt to equity ratio x0.60 1,401.4%  
Sales to assets ratio x0.40.8 53.2%   
Return on assets %11.810.1 116.1%  
Return on equity %-0.814.2 -6.0%  
Return on capital %22.317.3 128.8%  
Exports to sales %3.045.9 6.6%   
Imports to sales %0.416.6 2.6%   
Exports (fob) Rs m30717,308 1.8%   
Imports (cif) Rs m436,266 0.7%   
Fx inflow Rs m30717,308 1.8%   
Fx outflow Rs m1256,266 2.0%   
Net fx Rs m18111,042 1.6%   
CASH FLOW
From Operations Rs m11,7544,923 238.8%  
From Investments Rs m-561-1,563 35.9%  
From Financial Activity Rs m-6,762-1,832 369.1%  
Net Cashflow Rs m4,4321,528 290.1%  

Share Holding

Indian Promoters % 39.6 45.9 86.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 11.4 65.8%  
FIIs % 16.8 25.3 66.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 17.4 207.5%  
Shareholders   16,479 36,892 44.7%  
Pledged promoter(s) holding % 77.6 2.1 3,624.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   TTK HEALTHCARE  ALEMBIC  DR. REDDYS LAB  AJANTA PHARMA  SUVEN LIFE SCIENCES  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; TCS & Wipro Rally Over 3.5%(Closing)

Indian share markets recouped early losses during closing hours and ended today's volatile session higher, helped by gains in metals and banking stocks.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS